# 53. POTASSIUM METABOLISM

223
LABS
8.1 Ed. Authors/Editors
Michael Weinstock, MD
Kelsey Sicker, MD
53. POTASSIUM METABOLISM
— PART ONE: HYPERKALEMIA —
DEFINITION: Serum potassium ≥5.5mmol/L
SIGNS AND SYMPTOMS
Patient may have weakness and flaccid paralysis, abdominal distension and diarrhea.
Primarily diagnosed by laboratory and EKG changes (See below)
ETIOLOGY
Increased potassium intake: May result from salt substitutes, foods with high potassium
content, or iatrogenic parenteral replacement
Decreased potassium excretion: Usually due to impaired secretion resulting from either
Impaired sodium re-absorption: Decreased aldosterones (as seen in Addison’s
disease, use of potassium sparing diuretics, ACE inhibitors, NSAIDs, Heparin, or
Cyclosporine)
Increased chloride reabsorption: Renal insufficiency and diabetic nephropathy
Decreased distal flow rate: Seen in protein malnourished patients
Intra/Extracellular shift: Metabolic acidosis, insulin deficiency, exercise-induced
hyperkalemia, tumor lysis syndrome, rhabdomyolysis, ß-blockers, or Digoxin toxicity
Tissue damage: Crush injuries, rhabdomyolysis
Other causes (mechanism not clear): Lupus nephritis, chronic pyelonephritis, renal
transplantation, acute glomerulonephritis
Pseudohyperkalemia: Lab error, thrombocytosis and leukocytosis, hemolysis
(tourniquets, finger stick, delay between blood draw and analysis in lab). If bloodwork
becomes hemolyzed before it is processed, it may show a false mild hyperkalemia. In
these cases, consider short-term lab re-draw to confirm hyperkalemia before immediate
intervention
EVALUATION: Electrocardiogram is single most important factor in determining
seriousness of patient’s hyperkalemia
Review history looking for iatrogenic or physiologic reasons for hyperkalemia
Obtain EKG
Earliest changes are peaked T waves, with potassium level > 6.5mEq/L
Potassium level > 7–8mEq/L results in loss of P waves and widening of QRS complex
Potassium level > 8–10mEq/L may result in cardiac arrest
Repeat test if lab does not correlate with clinical picture. False potassium elevations may
be seen if blood sample is hemolyzed before analysis
Do not delay EKG and/or treatment while waiting for repeat labs to come back!
MANAGEMENT
Emergency management: Indicated for hyperkalemia associated with cardiac toxicity,
muscular paralysis or with severe hyperkalemia (> 6.5–7.0) without EKG changes
Non-Emergency management
224
LABS
— PART TWO: HYPOKALEMIA —
DEFINITION: Serum Potassium level < 3.5mEq/L
SIGNS AND SYMPTOMS
Potassium of 2.0–2.5mEq/L: Muscle weakness, hyporeflexia, fatigue, cramps
Potassium of < 2.0mEq/L: May cause areflexic paralysis, and respiratory insufficiency
may occur. Rate at which potassium declines has direct relationship to severity of muscular
abnormality
ETIOLOGY OF HYPOKALEMIA
Excess renal loss
Mineralocorticoid excess: Primary or secondary aldosteronism, renovascular HTN,
Bartter’s syndrome
Diuresis
Chronic metabolic alkalosis
Antibiotics: Gentamicin, Amphotericin B
Renal tubular acidosis
Hypomagnesemia
Other: Acute leukemia, ureterosigmoidostomy
Gastrointestinal losses: Vomiting, diarrhea
Extracellular to Intracellular fluid shifts: Acute alkalosis, hypokalemic periodic
paralysis, barium ingestion, insulin therapy or increased postprandial secretion of insulin,
Vitamin B12 therapy, thyrotoxicosis
Inadequate intake
EVALUATION
Review history looking for iatrogenic or physiologic reasons for hypokalemia
If unexplained hypokalemia (e.g., young patient taking no medications, no history of
vomiting), obtain a urinary potassium before repleting (hyperaldosteronism). If patient is
hypertensive, obtain a renin and aldosterone level (mineralocorticoid excess)
Consider checking ABG (pH and bicarbonate) in the unexplained hypokalemic patient
EKG changes associated with hypokalemia affect primarily repolarization segments of the
electrocardiogram
ST segment depression
T wave inversion
Elevation of the U wave
Hypokalemia greatly increases the incidence of Digitalis toxicity including junctional
rhythms or heart block
MANAGEMENT
Mild hypokalemia which is not symptomatic can be treated with PO replacement
K-Dur 20–40mEq PO daily—Sustained release: Not to be used in critical situations
Slow-K 8mEq—Sustained release: Not to be used in critical situations
K-Lyte (powder) 25–50mEq PO/NG: May be used for treating hypokalemia acutely
If patient is severely hypokalemic (< 3.0), or with evidence of cardiac symptoms,
replacement should be IV (on telemetry) with frequent lab checks
If patient is at risk of arrhythmia (history of heart failure, AFib) consider replacement
threshold below K of 4.0
Potassium deficit by level of serum potassium
Medications Used in Acute Treatment of Hyperkalemia
https://www.aafp.org/pubs/afp/issues/2006/0115/p283.pdf#page=7
(See Table 5 Pg.289)
Source: Hollander-Rodriguez JC, Calvert Jr. JF. Hyperkalemia. Am Fam Physician
2006;73(2):283-90. Copyright © 2006 American Academy of Family Physicians.
225
LABS
K+ = 3.0–3.5
Replace with 50–75mEq KCl
K+ = 2.5–3.0
Replace with 100–150mEq KCl
K+ = 2.0–2.5
Replace with 150–250mEq KCl
If magnesium level is low, Magnesium Oxide 400mg PO TID × 3–5 days
CLINICAL PEARLS
Consider replacing magnesium or calcium in patients with refractory hypokalemia
because potassium replacement will be ineffective if patient is also hypomagnesemic or
hypocalcemic
Because EKG manifestations of hypokalemia are often subtle, electrocardiogram should
not be used as a guide to replacement therapy
Arrhythmias may be more likely to occur in patients with hypokalemia who are also taking
Digoxin
Total amount of potassium in the body is 50 mcg/kg. About 95% is intracellular
References
Charytan D, Goldfarb DS. Indications for hospitalization of patients with hyperkalemia. Arch
Intern Med 2000;160(11):1605-11.
Clase CM, Carrero JJ, Ellison DH, et al. Conference participants. Potassium homeostasis and
management of dyskalemia in kidney diseases: Conclusions from a kidney disease:
Improving global outcomes (KDIGO) controversies conference. Kidney Int 2020;97(1):42-
61. doi: 10.1016/j.kint.2019.09.018. Epub 2019 Oct 10. PMID: 31706619.
Deriaz D, Guessous I, Vollenweider P, et al. Estimated 24-h urinary sodium and sodium-to-
potassium ratio are predictors of kidney function decline in a population-based study. J
Hypertens 2019;37(9):1853-60. doi: 10.1097/HJH.0000000000002098.PMID: 30964826.
Palmer BF, Carrero JJ, Clegg DJ, et al. Clinical management of hyperkalemia. Mayo Clin Proc
2021;96(3):744-62. doi: 10.1016/j.mayocp.2020.06.014. Epub 2020 Nov 5.
Perazella MA. Drug-induced hyperkalemia: Old culprits and new offenders. Am J Med
2000;109(4):307-14.
Stewart PM. Mineralocorticoid hypertension. Lancet 1999;353(9161):1341-7.
A diagnostic approach to a patient with hypokalemia
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5881435/pdf/ec-7-R135.pdf#page=7
(See Fig. 2 Pg. R141)
Source: Republished with permission of Bioscientifica Limited, from Kardalas E,
Stavroula AP, Panagiotis A, et al. Hypokalemia: A clinical update. Endocr Connect
[BIOSCIENTIFIC] 2018;7(4):R135–R146 at R138, Table 3. Copyright © 2018; permission
conveyed through Copyright Clearance Center, Inc.
226
G
227
GEN
GEN
8.1 Ed. Section Editor
Stephen Auciello, MD
54. Shortness of Breath ..................................................................................................229
55. Asthma in Adults.......................................................................................................233
56. Chronic Obstructive Pulmonary Disease (COPD)..................................................237
57. Evaluation of Chest Pain ..........................................................................................242
58. Hyperlipidemia...........................................................................................................246
59. Hypertension..............................................................................................................251
60. Coronary Artery Disease ..........................................................................................257
61. Heart Failure...............................................................................................................262
62. Atrial Fibrillation (AF)................................................................................................268
63. Ambulatory Post-Mi Management............................................................................274
64. Anemia........................................................................................................................277
65. Thyroid Disease and Testing....................................................................................281
66. Type 2 Diabetes Mellitus ..........................................................................................289
67. Headache Diagnosis and Management...................................................................306
68. Evaluation and Management of Dizziness ..............................................................312
69. Seizure Disorders......................................................................................................315
70. Gastroesophageal Reflux Disease and Peptic Ulcer Disease...............................319
71. Evaluation of Diarrhea in Adults..............................................................................327
V. Diagnosis and
Management of Common
Ambulatory Conditions
228
GEN
72. Constipation in Adults ..............................................................................................330
73. Hemorrhoids ..............................................................................................................332
74. Ocular Disorders and Screening..............................................................................335
75. Allergic Rhinitis/Seasonal Allergies ........................................................................340
76. Benign Prostatic Hyperplasia...................................................................................345
77. Management of Obesity In Adults............................................................................349
78. Adverse Drug Interactions and Prescribing Errors ...............................................354
79. Medication Adherence ..............................................................................................358
80. Non-opioid Medications for Chronic Non-Cancer Pain .........................................361
